Zydus Lifesciences and MSN Laboratories partner to Launch First Generic of Adempas (riociguat) in the U.S.A., PR Newswire, October 5, 2026

Zydus Lifesciences and MSN Laboratories have launched the first generic version of Adempas (riociguat) in the United States. The United States Food and Drug Administration (FDA) has approved it as equivalent to the original. Riociguat is used to treat adults with pulmonary arterial hypertension and with chronic thromboembolic pulmonary hypertension that is inoperable or persists […]

Zydus Lifesciences and MSN Laboratories partner to Launch First Generic of Adempas (riociguat) in the U.S.A., PR Newswire, October 5, 2026 Read Post »

Detecting pulmonary hypertension earlier? US Food and Drug Administration (FDA) clears Anumana’s AI echocardiogram algorithm

Anumana has received US Food and Drug Administration (FDA) 510(k) clearance for an AI-powered algorithm that detects early signs of pulmonary hypertension using standard 12-lead echocardiograms (ECGs) — making it the first pulmonary hypertension algorithm cleared for this widely available diagnostic tool. Previously granted US Food and Drug Administration “Breakthrough Device Designation”, the algorithm integrates

Detecting pulmonary hypertension earlier? US Food and Drug Administration (FDA) clears Anumana’s AI echocardiogram algorithm Read Post »

TRANSLATE »
Scroll to Top